The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib multicenter study of trifluridine/tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma (aGEC) after at least one line of treatment with a fluoropyrimidine and platinum containing regimen.
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche; QED Therapeutics; Signatera; Signatera
Speakers' Bureau - Amgen; Eisai; Exelixis; Genentech/Roche; ipsen; Signatera; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Kit Tam
No Relationships to Disclose
 
Edward Kim
Consulting or Advisory Role - ARMO BioSciences; Celgene; Eisai; Lilly; Pharmacyclics; Vicus Therapeutics
Speakers' Bureau - Celgene; Guardant Health
 
Parvin Keshtmand
No Relationships to Disclose
 
Samuel Ejadi
No Relationships to Disclose
 
Fa Chyi Lee
No Relationships to Disclose
 
May Thet Cho
Consulting or Advisory Role - Amgen; Astellas Pharma; Eisai; Exelixis; Ipsen; Taiho Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); incyte (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune